VNDA
FDA said yes, and the market hit the gas
Vanda Pharmaceuticals got the kind of news biotech investors live for: FDA approval for BYSANTI. The drug is approved for treating Bipolar I manic episodes and schizophrenia symptoms in adults, which gives the company a new commercial shot on goal.
Why traders got excited
The stock jumped 44% in after-hours trading, so clearly the market thinks this is more than just a nice regulatory checkbox. The big hook here is that the FDA tagged BYSANTI as a New Chemical Entity, which gives it patent protection stretching to 2044. Translation: fewer generic copycats circling the drain for a long while.
The moat is the story
That long runway matters because drug approvals are one thing, but durable exclusivity is where the real money can get interesting. A product with nearly two decades of protection can give a small-cap biotech a much better chance of building a real business instead of just chasing one-off headlines.
Big picture
This is Vanda trying to turn FDA paperwork into recurring cash flow. If BYSANTI launches well, investors may start thinking less “speculative biotech” and more “company with an actual moat.”